Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 41.15 CHF -0.48%
Market Cap: 498.8m CHF
Have any thoughts about
Basilea Pharmaceutica AG?
Write Note

Intrinsic Value

The intrinsic value of one BSLN stock under the Base Case scenario is 74.83 CHF. Compared to the current market price of 41.15 CHF, Basilea Pharmaceutica AG is Undervalued by 45%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BSLN Intrinsic Value
74.83 CHF
Undervaluation 45%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Basilea Pharmaceutica AG

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
BSLN
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for BSLN cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about BSLN?
Bearish
Neutral
Bullish

Fundamental Analysis

41.15 CHF
-0.48%
-0.48%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Basilea Pharmaceutica AG
CH
Biotechnology
Market Cap
498.8m CHF
IPO
Mar 25, 2004
Employees
154
Switzerland
Market Cap
498.8m CHF
Industry
Biotechnology
IPO
Mar 25, 2004
Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Basilea Pharmaceutica AG

Provide an overview of the primary business activities
of Basilea Pharmaceutica AG.

What unique competitive advantages
does Basilea Pharmaceutica AG hold over its rivals?

What risks and challenges
does Basilea Pharmaceutica AG face in the near future?

Summarize the latest earnings call
of Basilea Pharmaceutica AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Basilea Pharmaceutica AG.

Provide P/S
for Basilea Pharmaceutica AG.

Provide P/E
for Basilea Pharmaceutica AG.

Provide P/OCF
for Basilea Pharmaceutica AG.

Provide P/FCFE
for Basilea Pharmaceutica AG.

Provide P/B
for Basilea Pharmaceutica AG.

Provide EV/S
for Basilea Pharmaceutica AG.

Provide EV/GP
for Basilea Pharmaceutica AG.

Provide EV/EBITDA
for Basilea Pharmaceutica AG.

Provide EV/EBIT
for Basilea Pharmaceutica AG.

Provide EV/OCF
for Basilea Pharmaceutica AG.

Provide EV/FCFF
for Basilea Pharmaceutica AG.

Provide EV/IC
for Basilea Pharmaceutica AG.

Show me price targets
for Basilea Pharmaceutica AG made by professional analysts.

What are the Revenue projections
for Basilea Pharmaceutica AG?

How accurate were the past Revenue estimates
for Basilea Pharmaceutica AG?

What are the Net Income projections
for Basilea Pharmaceutica AG?

How accurate were the past Net Income estimates
for Basilea Pharmaceutica AG?

What are the EPS projections
for Basilea Pharmaceutica AG?

How accurate were the past EPS estimates
for Basilea Pharmaceutica AG?

What are the EBIT projections
for Basilea Pharmaceutica AG?

How accurate were the past EBIT estimates
for Basilea Pharmaceutica AG?

Compare the revenue forecasts
for Basilea Pharmaceutica AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Basilea Pharmaceutica AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Basilea Pharmaceutica AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Basilea Pharmaceutica AG compared to its peers.

Compare the P/E ratios
of Basilea Pharmaceutica AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Basilea Pharmaceutica AG with its peers.

Analyze the financial leverage
of Basilea Pharmaceutica AG compared to its main competitors.

Show all profitability ratios
for Basilea Pharmaceutica AG.

Provide ROE
for Basilea Pharmaceutica AG.

Provide ROA
for Basilea Pharmaceutica AG.

Provide ROIC
for Basilea Pharmaceutica AG.

Provide ROCE
for Basilea Pharmaceutica AG.

Provide Gross Margin
for Basilea Pharmaceutica AG.

Provide Operating Margin
for Basilea Pharmaceutica AG.

Provide Net Margin
for Basilea Pharmaceutica AG.

Provide FCF Margin
for Basilea Pharmaceutica AG.

Show all solvency ratios
for Basilea Pharmaceutica AG.

Provide D/E Ratio
for Basilea Pharmaceutica AG.

Provide D/A Ratio
for Basilea Pharmaceutica AG.

Provide Interest Coverage Ratio
for Basilea Pharmaceutica AG.

Provide Altman Z-Score Ratio
for Basilea Pharmaceutica AG.

Provide Quick Ratio
for Basilea Pharmaceutica AG.

Provide Current Ratio
for Basilea Pharmaceutica AG.

Provide Cash Ratio
for Basilea Pharmaceutica AG.

What is the historical Revenue growth
over the last 5 years for Basilea Pharmaceutica AG?

What is the historical Net Income growth
over the last 5 years for Basilea Pharmaceutica AG?

What is the current Free Cash Flow
of Basilea Pharmaceutica AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Basilea Pharmaceutica AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Basilea Pharmaceutica AG

Current Assets 155m
Cash & Short-Term Investments 63m
Receivables 48.9m
Other Current Assets 43.1m
Non-Current Assets 33.7m
PP&E 19.4m
Intangibles 473k
Other Non-Current Assets 13.8m
Current Liabilities 37.8m
Accounts Payable 11.5m
Accrued Liabilities 12m
Other Current Liabilities 14.3m
Non-Current Liabilities 134.1m
Long-Term Debt 95.7m
Other Non-Current Liabilities 38.4m
Efficiency

Earnings Waterfall
Basilea Pharmaceutica AG

Revenue
149m CHF
Cost of Revenue
-34.9m CHF
Gross Profit
114.1m CHF
Operating Expenses
-122.5m CHF
Operating Income
-8.4m CHF
Other Expenses
7.8m CHF
Net Income
-652k CHF

Free Cash Flow Analysis
Basilea Pharmaceutica AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BSLN Profitability Score
Profitability Due Diligence

Basilea Pharmaceutica AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Positive Revenue Growth Forecast
Positive 3-Years Revenue Growth
40/100
Profitability
Score

Basilea Pharmaceutica AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

BSLN Solvency Score
Solvency Due Diligence

Basilea Pharmaceutica AG's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Positive Net Debt
Long-Term Solvency
High D/E
29/100
Solvency
Score

Basilea Pharmaceutica AG's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BSLN Price Targets Summary
Basilea Pharmaceutica AG

Wall Street analysts forecast BSLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BSLN is 88.27 CHF with a low forecast of 52.52 CHF and a high forecast of 126 CHF.

Lowest
Price Target
52.52 CHF
28% Upside
Average
Price Target
88.27 CHF
115% Upside
Highest
Price Target
126 CHF
206% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BSLN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BSLN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one BSLN stock?

The intrinsic value of one BSLN stock under the Base Case scenario is 74.83 CHF.

Is BSLN stock undervalued or overvalued?

Compared to the current market price of 41.15 CHF, Basilea Pharmaceutica AG is Undervalued by 45%.

Back to Top